Evidence map›Paper›PMID 33334813›Full record

ReviewCancer research2021

Cancer-Associated Neurogenesis and Nerve-Cancer Cross-talk.

Deborah A Silverman, Vena K Martinez, Patrick M Dougherty, Jeffrey N Myers, George A Calin, Moran Amit

Registry-linked trialOpen access · bronzeAbstract readReview
In one paragraph

Review in Cancer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07187284 (Evaluating Endervascular Denervation), which is not on this map. Cited by 170 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
170citing papers in PubMed, 1 pooled it
13.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07187284 phase1 / phase2not yet recruitingnot on this mapstarted 2025, after this paper: background citation

Evaluating Endervascular Denervation (EDN) Combined With Transarterial Intervention (TACE/HAIC) and Second-Line Immune-Targeted Therapy in Locally Advanced Hepatocellular Carcinoma (HCC) With Portal Vein Tumor Thrombosis After Progression on First-Line Systemic Therapy: A Prospective, Multicenter, Randomized Controlled Study

TypeinterventionalSponsorZhongda HospitalRan2025 to 2027Enrolled62ConditionsHCC - Hepatocellular CarcinomaArmsEDN combined with TACE/HAIC and Immuno-Targeted Therapy, TACE/HAIC plus Immuno-Targeted Therapy
3 · Its place in the literature

Who cites it

170 citing papers in PubMed, 1 synthesis or guideline pooled it, 245 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. [Research progress of gelatin composites in promoting peripheral nerve regeneration].Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery · 2026
    Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Molecular maps of diseases from omics data and network embeddings.NPJ systems biology and applications · 2026
    Article
  19. Article
  20. Article

110 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Deborah A Silverman *Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-2467-2445
Vena K Martinez *Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Patrick M DoughertyDepartment of Pain Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Jeffrey N MyersDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-4767-3408
George A CalinDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-7427-0578
Moran AmitDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas. mamit@mdanderson.org.
The University of Texas MD Anderson Cancer Center · US

Funding

Defining the Role of Tumor-Neutral Crosstalk in head and Neck Cancer Progression and Treatment ResistanceR37CA242006 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI AMIT, MORAN · 2020 to 2025
$3.4M
Novel extra cellular RNA-based combinatorial RNA inhibition therapyUH3TR000943 · NCATS · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI CALIN, GEORGE A., LOPEZ-BERESTEIN, GABRIEL · 2015 to 2017
$3.2M
Protein-coding and non-coding RNA biomarkers for early detection of CLLR01CA182905 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI ABRUZZO, LYNNE V., CALIN, GEORGE A. · 2014 to 2018
$2.9M
miR-155 targeted therapeutics for precision medicine in lung cancerR01CA222007 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI CALIN, GEORGE A., CRISTINI, VITTORIO · 2018 to 2022
$2.6M
Viral miRs and cellular miRs in sepsisR01GM122775 · NIGMS · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI CALIN, GEORGE A., LUPU, FLOREA · 2018 to 2020
$1.1M
The Role of Mutant p53 in Regulating T-cell Immune Evasion in Pancreatic Adenocarcinoma and Other CancersF30CA228258 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SILVERMAN, DEBORAH ANN · 2019 to 2022
$100k
NCATS NIH HHS UH3 TR000943NCI NIH HHS F30 CA228258NCI NIH HHS R01 CA182905NCI NIH HHS R01 CA222007NCI NIH HHS R37 CA242006NIGMS NIH HHS R01 GM122775
6 · The paper itself

Abstract

In this review, we highlight recent discoveries regarding mechanisms contributing to nerve-cancer cross-talk and the effects of nerve-cancer cross-talk on tumor progression and dissemination. High intratumoral nerve density correlates with poor prognosis and high recurrence across multiple solid tumor types. Recent research has shown that cancer cells express neurotrophic markers such as nerve growth factor, brain-derived neurotrophic factor, and glial cell-derived neurotrophic factor and release axon-guidance molecules such as ephrin B1 to promote axonogenesis. Tumor cells recruit new neural progenitors to the tumor milieu and facilitate their maturation into adrenergic infiltrating nerves. Tumors also rewire established nerves to adrenergic phenotypes via exosome-induced neural reprogramming by p53-deficient tumors. In turn, infiltrating sympathetic nerves facilitate cancer progression. Intratumoral adrenergic nerves release noradrenaline to stimulate angiogenesis via VEGF signaling and enhance the rate of tumor growth. Intratumoral parasympathetic nerves may have a dichotomous role in cancer progression and may induce Wnt-β-catenin signals that expand cancer stem cells. Importantly, infiltrating nerves not only influence the tumor cells themselves but also impact other cells of the tumor stroma. This leads to enhanced sympathetic signaling and glucocorticoid production, which influences neutrophil and macrophage differentiation, lymphocyte phenotype, and potentially lymphocyte function. Although much remains unexplored within this field, fundamental discoveries underscore the importance of nerve-cancer cross-talk to tumor progression and may provide the foundation for developing effective targets for the inhibition of tumor-induced neurogenesis and tumor progression.

Indexed as

NeurogenesisAnimalsAutonomic DenervationBiomarkers, TumorCell Line, TumorDisease Models, AnimalDisease ProgressionFeedback, PhysiologicalHumansNeoplasmsNeoplastic Stem CellsNeovascularization, PathologicParasympathetic Nervous SystemSympathetic Nervous SystemXenograft Model Antitumor AssaysBiomarkers, Tumor

Identifiers

PMID33334813
PMCPMC7969424
OpenAlexW3112735128

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.